Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 16/20 | 0.60 |
| ▸ | TPO | P07202 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | EPX | P11678 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18617439 | 0.92 | MPO (0.56) | MPOTPOCYP3A4EPX | |
| SCHEMBL18586508 | 0.92 | MPO (0.56) | MPOTPOCYP3A4EPX | |
| SCHEMBL18586829 | 0.90 | MPO (0.61) | MPOTPOCYP3A4EPX | |
| SCHEMBL18620306 | 0.87 | MPO (0.60) | MPOTPOCYP3A4EPX | |
| SCHEMBL18617587 | 0.85 | MPO (0.58) | MPOTPOCYP3A4KLKB1 | |
| SCHEMBL18621239 | 0.84 | MPO (0.60) | MPOTPOCYP3A4EPX | |
| SCHEMBL18618933 | 0.84 | MPO (0.64) | MPOTPOCYP3A4EPXKLKB1 | |
| SCHEMBL20515418 | 0.84 | MPO (0.44) | MPOTPOCYP3A4EPX | |
| SCHEMBL20515410 | 0.84 | MPO (0.58) | MPOTPOCYP3A4EPX | |
| SCHEMBL18620313 | 0.83 | MPO (0.64) | MPOTPOCYP3A4EPX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180282320-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282320-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MPO 2/4885TPO 7/4885CYP3A4 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.